Additional file 2: of Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1

Figure S1. Incremental quarterly relapse count over 1 year. (PDF 145 kb)